DNA Stock Risk & Deep Value Analysis
Ginkgo Bioworks Holdings Inc
DVR Score
out of 10
The Bottom Line on DNA
We analyzed Ginkgo Bioworks Holdings Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran DNA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
DNA Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
DNA Deep Value Analysis
Compare DNA to Similar Stocks
See how Ginkgo Bioworks Holdings Inc stacks up against related companies in our head-to-head analysis.
DNA Red Flags & Warning Signs
- âš
Missed Q4 2025 earnings expectations or negative forward guidance
- âš
Further significant shareholder dilution to fund operations
- âš
Failure of key partnership programs to achieve milestones or commercialization
- âš
Increased competitive pressure from new synthetic biology platforms or in-house capabilities
Unlock DNA Red Flags & Risk Warnings
Create a free account to see the full analysis
DNA Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
4 Identified
Ginkgo's moat is built on its proprietary Foundry, extensive data, and IP in biological engineering. Its durability relies on continuously expanding its capabilities and dataset faster than competitors, driving down costs and improving success rates. Switching costs for customers are increasing as they integrate Ginkgo's platform into their R&D pipelines.
DNA Competitive Moat Analysis
Sign up to see competitive advantages
DNA Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated: late February/early March 2026)
- •Announcement of new, large-scale Foundry programs or strategic partnerships
- •Significant progress updates on existing commercial programs (e.g., reaching specific output titers)
Medium-Term (6-18 months)
- •Expansion of biomanufacturing scale-up capabilities, reducing cost per unit
- •Successful commercialization of initial derived products from Foundry programs
- •Acquisition or partnership to expand specific biological capabilities or market reach
Long-Term (18+ months)
- •Ginkgo's Foundry becoming the industry standard platform for biological engineering, similar to AWS for cloud computing
- •Disruption of traditional chemical and pharmaceutical manufacturing processes through bio-based alternatives
- •Entry into new high-value markets (e.g., sustainable aviation fuel, advanced materials)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
DNA Bull Case: What Could Go Right
- ✓
Acceleration in Foundry program growth (especially new, large programs)
- ✓
Significant improvements in gross margins and reduced cash burn
- ✓
Evidence of successful commercialization of derived products, demonstrating platform value
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
